Michael W. Pennington joined Peptides International in December 2010 serving as Chief Technology Officer. In January 2011, he was appointed President and C.O.O. and in January 2013, he was appointed President and C.E.O of the same.
After doctoral research at University of Florida, he joined the pharmaceutical industry in the Department of Biotechnology at Schering-Plough in 1988. In late 1989, he joined Bachem Bioscience in King of Prussia, PA as a Principle Scientist in the Peptide Chemistry department. He served as the Group Director for Bachem Bioscience from 1992-2000 before being appointed as President and C.O.O. a positioned he maintained from 2000 – 2010. He built and directed an internationally recognized peptide chemistry team focused on producing complex peptides and toxins. Dr. Pennington was a member of Bachem Forschungausschuss, the International Research and Development from 2000 – 2010. He has extensive collaborations with both industrial and academic scientists and maintains an extramurally funded research program on several peptide toxins. He is a founder of Airmid Inc, a biotech venture company dedicated to advancing two of his discoveries into clinical development for autoimmune diseases.
Dr. Pennington has been awarded five patent and over 90 peer reviewed scientific articles, and serves as an editor of International Journal of Peptide Research and Therapeutics and Current Peptide and Protein Letters. He holds a Bachelors Degree in Chemistry degree from the University of North Carolina @ Chapel Hill and a Ph.D. from University of Florida @ Gainesville.